Clinical Trial Update: Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating Sacituzumab Tirumotecan in locally advanced or metastatic thymic carcinoma; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thymic Carcinoma

Drugs mentioned

• Sacituzumab Tirumotecan (Sacituzumab govitecan)

Snippet

Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Conditions: Thymic Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING